Feline oral squamous cell carcinoma is a devastating and painful cancer. There are few available treatments, and there is no cure. Affected cats usually do not live more than six months. Researchers will investigate a novel therapeutic approach incorporating dasatinib, a small-molecule tyrosine kinase inhibitor, into treatment. Dasatinib has shown promise in treating oral squamous cell carcinoma in humans, and this research focuses on the drug's potential as a novel therapy for treating this disease in cats.
Study ID
D14FE-015
Study Status
Complete
Start Date
09/01/2013
Grant amount awarded
$48,181
Grant recipient
Oregon State University
Study country
United States
Investigator
Stuart C. Helfand, DVM
Study category
Cancer